PharVision Advisers LLC Purchases Shares of 33,100 Teladoc Health, Inc. (NYSE:TDOC)

PharVision Advisers LLC acquired a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 33,100 shares of the health services provider’s stock, valued at approximately $301,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Arkadios Wealth Advisors purchased a new stake in Teladoc Health during the fourth quarter worth $115,000. Nisa Investment Advisors LLC boosted its stake in shares of Teladoc Health by 20,936.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 426,206 shares of the health services provider’s stock worth $3,874,000 after acquiring an additional 424,180 shares in the last quarter. Westside Investment Management Inc. grew its position in shares of Teladoc Health by 43.8% during the 4th quarter. Westside Investment Management Inc. now owns 9,200 shares of the health services provider’s stock valued at $84,000 after acquiring an additional 2,800 shares during the period. KBC Group NV increased its stake in shares of Teladoc Health by 72.3% in the 4th quarter. KBC Group NV now owns 8,849 shares of the health services provider’s stock valued at $80,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of Teladoc Health by 21.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 700,166 shares of the health services provider’s stock valued at $6,365,000 after purchasing an additional 125,111 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Insider Activity

In other news, insider Adam C. Vandervoort sold 11,011 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total value of $92,712.62. Following the transaction, the insider now owns 64,308 shares of the company’s stock, valued at $541,473.36. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.58% of the company’s stock.

Teladoc Health Stock Down 4.8%

Shares of NYSE:TDOC opened at $6.99 on Thursday. Teladoc Health, Inc. has a 52-week low of $6.35 and a 52-week high of $15.21. The stock has a market cap of $1.23 billion, a P/E ratio of -1.21 and a beta of 1.82. The business has a fifty day moving average of $7.49 and a two-hundred day moving average of $9.32. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The firm had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. On average, research analysts expect that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.

Analyst Ratings Changes

TDOC has been the topic of several research analyst reports. Stifel Nicolaus dropped their price objective on Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Thursday, May 1st. Royal Bank of Canada increased their target price on Teladoc Health from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. Piper Sandler reduced their price objective on shares of Teladoc Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. The Goldman Sachs Group dropped their target price on shares of Teladoc Health from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. Finally, Canaccord Genuity Group lowered their price objective on Teladoc Health from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Twelve equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Teladoc Health has an average rating of “Hold” and a consensus price target of $9.71.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.